Spesolimab-sbzo was initially approved in 2022 for treating flares of generalized pustular psoriasis in adults.
The US Food and Drug Administration has approved spesolimab-sbzo, an interleukin -36 receptor antagonist, for the treatment of generalized pustular psoriasis in adults and in pediatric patients aged ≥ 12 years who weigh ≥ 40 kg, according to an announcement from the manufacturer., the product is an injectable antibody that blocks the IL-36 receptor, a key part of the pathway shown to be involved in the cause of GPP, which is rare and is a potentially-life-threatening disease.
Spesolimab-sbzo is currently available in 48 countries, according to the Boehringer Ingelheim release, which states that the approval makes it the firstAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Expands Use of Asthma Med Xolair to Treat Food AllergiesPeople threatened by accidental exposure to foods they're allergic to may have a new weapon of defense: On Friday, the U.S. Food and Drug Administration expanded the use of the asthma drug Xolair to help prevent anaphylactic reactions.
Read more »
In an unusual move, FDA postpones approval decision for Lilly’s Alzheimer’s drugBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Eli Lilly says Alzheimer’s drug approval delayed as FDA seeks input from advisersDrugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the FDA plans to call a last-minute meeting of its advisers
Read more »
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drugWegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Read more »
Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drugThe injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.
Read more »
Abortion Rights Defenders, House Dems Blast Ruling Annulling FDA's Mifepristone ApprovalBrett Wilkins is a staff writer for Common Dreams.
Read more »